ES471243A1 - Un procedimiento para la preparacion de un peptido - Google Patents

Un procedimiento para la preparacion de un peptido

Info

Publication number
ES471243A1
ES471243A1 ES471243A ES471243A ES471243A1 ES 471243 A1 ES471243 A1 ES 471243A1 ES 471243 A ES471243 A ES 471243A ES 471243 A ES471243 A ES 471243A ES 471243 A1 ES471243 A1 ES 471243A1
Authority
ES
Spain
Prior art keywords
phe
peptides
ser gly
amino acid
gly ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES471243A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beecham Group PLC
Original Assignee
Beecham Group PLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beecham Group PLC filed Critical Beecham Group PLC
Publication of ES471243A1 publication Critical patent/ES471243A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065—Purification, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • C07K5/06069—Ser-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1013—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing O or S as heteroatoms, e.g. Cys, Ser
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00—Peptide or protein sequence
    • Y10S930/01—Peptide or protein sequence
    • Y10S930/32—Modification to prevent enzymatic degradation

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un procedimiento para la preparación de un péptido de fórmula (I): X-R-R1-R2-R3-Y (I) y sales del mismo, constituido por 6 a 12 restos de aminoácidos naturales, donde R es un grupo opcionalmente presente, capaz de comunicar a un péptido resistencia a la descomposición enzimática; R1 representa un resto de un aminoácido básico, opcionalmente ligado a uno o más restos de aminoácidos no hidrófobos neutros y/o aminoácidos básicos; R2 representa un resto de un aminoácido no hidrófobo neutro, opcionalmente ligado a uno de más restos de otros aminoácidos no hidrófobos neutros; R3 representa un resto de un aminoácido hidrófobo, opcionalmente ligado a uno o más restos de aminoácidos no hidrófobos neutros y/o aminoácidos hidrófobos; X es hidrógeno o un grupo N=protector es Y hidroxilo o un grupo protector del C terminal; cuyo procedimiento consiste en someter a reacción de copulación los aminoácidos constituyentes en el orden correcto para formar el péptido deseado, estando protegidos cualquier grupoamino o grupo carboxilo que no participe en las reacciones de copulación, y después, si se desea, separar estos grupos protectores y, si se desea, formar la sal deseada del péptido.
ES471243A 1977-06-29 1978-06-28 Un procedimiento para la preparacion de un peptido Expired ES471243A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB2714077 1977-06-29

Publications (1)

Publication Number Publication Date
ES471243A1 true ES471243A1 (es) 1979-10-01

Family

ID=10254870

Family Applications (1)

Application Number Title Priority Date Filing Date
ES471243A Expired ES471243A1 (es) 1977-06-29 1978-06-28 Un procedimiento para la preparacion de un peptido

Country Status (13)

Country Link
US (1) US4223016A (es)
EP (1) EP0000252B1 (es)
JP (1) JPS5416402A (es)
AU (1) AU522641B2 (es)
CA (1) CA1105006A (es)
DE (1) DE2861593D1 (es)
DK (1) DK292778A (es)
ES (1) ES471243A1 (es)
IE (1) IE47105B1 (es)
IL (1) IL54967A (es)
IT (1) IT7850095A0 (es)
NZ (1) NZ187638A (es)
ZA (1) ZA783699B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56119178U (es) * 1980-02-13 1981-09-11
US4752601A (en) * 1983-08-12 1988-06-21 Immunetech Pharmaceuticals Method of blocking immune complex binding to immunoglobulin FC receptors
US4683292A (en) * 1983-08-12 1987-07-28 Immunetech, Inc. Immunotherapeutic polypeptide agents which bind to lymphocyte immunoglobulin FC receptors
EP0190127A1 (en) * 1984-08-10 1986-08-13 MERCK PATENT GmbH Immunotherapeutic polypeptide agents
US5955076A (en) * 1989-06-15 1999-09-21 Peptide Therapeutics Limited Immunoactive peptides and antibodies and their use in anti-allergy treatment
GB8913737D0 (en) * 1989-06-15 1989-08-02 Univ Birmingham A novel anti-allergy treatment
GB9422294D0 (en) * 1994-11-04 1994-12-21 Peptide Therapeutics Ltd Peptides for anti-allergy treatment
WO1997025999A1 (en) * 1996-01-16 1997-07-24 Rensselaer Polytechnic Institute Peptides for altering osteoblast adhesion
RU2193413C2 (ru) 1996-03-01 2002-11-27 Новартис Аг Пептидные иммуногены для вакцинации и лечения аллергии
US6573372B2 (en) 1999-01-07 2003-06-03 Heska Corporation Feline immunoglobulin E molecules and compositions there of
RU2309144C2 (ru) * 2005-03-25 2007-10-27 Общество С Ограниченной Ответственностью "Фарминтерпрайсез" Фенилсодержащие n-ацильные производные аминов, способ их получения, фармацевтическая композиция и их применение в качестве противовоспалительных и анальгетических средств
US7425020B2 (en) 2006-04-25 2008-09-16 Mats Lindkvist Steering wheel suspension system
ES2304223B2 (es) 2007-03-08 2009-05-01 Universidad De Sevilla Nuevos caramelos con elevado contenido en oligosacaridos prebioticos, procedimiento de preparacion y utilizacion.

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL6501206A (es) * 1964-02-12 1965-08-13
NL6509727A (es) * 1965-07-28 1967-01-30
US3832337A (en) * 1970-07-28 1974-08-27 Squibb & Sons Inc Peptide enzyme inhibitors
JPS5648502B2 (es) * 1972-01-17 1981-11-16
US3864481A (en) * 1972-12-14 1975-02-04 St Lukes Hospital Anti disease producing synthetic material for the prevention suppression and diagnosis of multiple sclerosis and method of treatment therefor
US3987014A (en) * 1974-01-10 1976-10-19 Becton, Dickinson And Company Secretin intermediates and derivatives
US4113858A (en) * 1975-01-20 1978-09-12 St. Luke's Hospital Novel compounds, compositions and methods of their use
DE2649146A1 (de) * 1975-10-29 1977-05-12 Parke Davis & Co Nonapeptide
SE436645C (sv) * 1976-04-29 1996-07-22 Bonnierfoeretagen Ab Antigeniskt aktiv polypeptid, som kan användas vid cancerdiagnosticering och vid framställning av antikroppar
US4059693A (en) * 1976-06-11 1977-11-22 University Patents, Inc. Analgesic action of substance P
US4087419A (en) * 1976-11-05 1978-05-02 Parke, Davis & Company Heptapeptides and methods for their production

Also Published As

Publication number Publication date
EP0000252B1 (en) 1982-02-03
DE2861593D1 (en) 1982-03-11
IL54967A0 (en) 1978-08-31
NZ187638A (en) 1981-07-13
US4223016A (en) 1980-09-16
IT7850095A0 (it) 1978-06-29
IE781290L (en) 1978-12-29
AU522641B2 (en) 1982-06-17
IL54967A (en) 1982-03-31
JPS5416402A (en) 1979-02-07
DK292778A (da) 1978-12-30
CA1105006A (en) 1981-07-14
ZA783699B (en) 1979-06-27
EP0000252A1 (en) 1979-01-10
AU3762878A (en) 1980-01-03
IE47105B1 (en) 1983-12-28

Similar Documents

Publication Publication Date Title
Marks et al. Enzymatic mechanisms for the inactivation of luteinizing hormone-releasing hormone (LH-RH)
ES471243A1 (es) Un procedimiento para la preparacion de un peptido
DE2617646C2 (de) Nonapeptid-amide und Decapeptid-amide mit Gonadoliberin-Wirkung, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Präparate
Isowa et al. The synthesis of peptides by means of proteolytic enzymes.
US3926938A (en) Synthesis of salmon calcitonin
CA2064473A1 (en) Chimeric amino acids and peptides containing these analogues
AU633913B2 (en) Novel tnf-inhibit proteins and their preparation
KR880009045A (ko) 혈액 응고 방지성 펩티드
ES8501364A1 (es) Un metodo para la preparacion de nuevos polipeptidos.
EP0317573B1 (en) Antipyretic and anti-inflammatory peptides
DE69715860D1 (de) Verfahren zur herstellung von peptiden
GB1584968A (en) Pentapeptides processes for their preparation and pharmaceutical compositions containing them
US4203975A (en) Psychopharmacological peptides suitable for therapeutic administration
Aoyagi et al. Studies of Peptide Antibiotics. III. Cyclo-(L-valyl-L-ornithyl-L-leucyl-D-phenylalanylglycyl) 2
US3915949A (en) Solid phase synthesis of ACTH
US4016259A (en) Contraceptive polypeptides
ATE47880T1 (de) Vorlaeufer eines an dem c-ende amidierten peptids und dessen herstellung.
ES8607342A1 (es) Procedimiento para preparar peptidos, utilizables como pro- ductos intermedios en la sintesis de gonadorelina o de sus compuestos analogos
US3268502A (en) Undecapeptides
US3810880A (en) Process for the preparation of human acth and protected human acth
US3738978A (en) Process for the manufacture of peptides
EP0015036B1 (en) Psycho-pharmacological peptides, process for their preparation and therapeutical compositions containing them
Sugano et al. Synthesis and Biological Activity of Peptides Related to Eledoisin. II. Hexapeptide Amides Containing N-Methylamino Acids
Benoiton et al. 666. Polypeptides. Part V. The synthesis of some acetylserine peptides related to the active centre of chymotrypsin
FR2268792A1 (en) Peptides enzymatic synthesis - by reacting peptide free acids with amino acids or peptides in the presence of pepsin